Relationship of TTF-1 and EGFR on Lung Adenocarcinoma at Dr. Saiful Anwar General Hospital Malang
DOI:
https://doi.org/10.21776/ub.jkb.2020.031.01.9Keywords:
Epidermal Growth Factor Receptor (EGFR), lung adenocarcinoma, Thyroid Transcription Factor-1 (TTF-1)Abstract
There is a correlation between mutation of Epidermal Growth Factor Receptor (EGFR) and lung adenocarcinoma. Unfortunately, examination for EGFR mutation is difficult because surgery must be conducted to obtain the best specimen. Thyroid Transcription Factor-1 (TTF-1) is a marker for lung adenocarcinoma. This observational study took place at Dr. Saiful Anwar Hospital from stored biological materials from 2013-2018. Samples were lung adenocarcinoma patients that undergo EGFR examination. Data then analyzed using Fischer's Exact Test to determine the relationship between EGFR and TTF-1. Specificity/sensitivity value is 0.75/0.90, p: 0.617, odds ratio 0.333 (0.032-3.515). However, Receiver Operating Characteristic (ROC) curve of TTF- 1 show AUC 0.614 (95CI, 0.35- 0.878). TTF-1 examination has a moderate strength in determining EGFR mutation on lung adenocarcinoma patients at Dr. Saiful Anwar Hospital.    Â
Downloads
References
Jazieh AR, Sudairy RA, Shraie NA, Suwairi W, Ferwana M, and Murad HM. Erlotinib In Wild Type Epidermal Growth Factor Receptor Non‑Small Cell Lung Cancer: A Systematic Review, Annals of Thoracic Medicine. 2013; 8 : 204-208.
Jusuf A, Syahrudin E, Agun W., Aziza GL et al. Kanker Paru: Pedoman Diagnosis & Penatalaksanaan di Indonesia. Edisi Revisi III. 2011. PDPI, Jakarta.
Listyoko A, Herman and Prasetya F. Profil Kanker Paru di RSSA 2015. 2017.
Pan YQ, Shi WW, Xu DP, Xu HH, Zhou MY, and Yan WH. Associations between Epidermal Growth Factor Receptor Gene Mutation and Serum Tumor Markers in Advanced Lung Adenocarcinomas: A Retrospective Study, Chinese Medical Science Journal. 2014; 29(3) : 156 – 161.
Bethune G, Bethune D, Ridgway N, Xu Z. 2010. Epidermal Growth Factor Receptor (EGFR) In Lung Cancer: An Overview and Update, Journal of Thorax Disease. 2010; 2 : 48 – 51.
Ilonen I. Non-Small Cell Lung Cancer: Studies On Pathogenesis, Tumour Targeting and Treatment Outcomes. Faculty of Medicine Helsinki Finland. 2011; 149 : 1-76.
Al Olayan A, Al Hussaini H, and Jazieh AR. The Roles of Epidermal Growth Factor Receptor (EGFR) Inhibitors In The Management of Lung Cancer. Journal of Infection and Public Health. 2012; 5: 550-560
Yamaguchi T, Yanagisawa K, Sugiyama R, et al. NKX2-1/TITF1/TTF-1-induced ROR 1 is required to sustain EGFR survival signaling in Lung Adenocarcinoma. Cancer cell 21. 2012; 348-361. Elsevier inc.
Syahrudin E, Wulandari L, Muktiati NS, et al. Uncommon EGFR mutations in cytological specimens of 1874 newly diagnosed Indonesian Lung Cancer Patients. Dove press. 2018; Lung cancer:Targets and Therapy 2018: 9 25-3.
Pan JB, Hou YH, Zhang GJ. Correlation Between EGFR Mutations and Serum Tumor Markers in Lung Adenocarcinoma Patients, Asian Pacific Journal of Cancer Prevention. 2013; 14 : 695–670.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
